<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04274101</url>
  </required_header>
  <id_info>
    <org_study_id>Nifurtimox vs. Benznidazole</org_study_id>
    <nct_id>NCT04274101</nct_id>
  </id_info>
  <brief_title>Nifurtimox Versus Benznidazole Effectiveness and Tolerance for Chagas Disease Treatment</brief_title>
  <official_title>Nifurtimox Versus Benznidazole Effectiveness and Tolerance for Chagas Disease Treatment, Retrospective Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Niños R. Gutierrez de Buenos Aires</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Niños R. Gutierrez de Buenos Aires</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chagas disease is caused by parasite Trypanosoma Cruzi. In Argentina, there is an estimated
      of 1.600.000 infected people. Due to migration phenomenon, most cases live in urban areas
      without vectorial transmission.

      Pharmacological treatment is given to prevent development of cardiac and gastrointestinal
      sequelae. There are two available drugs for this disease; Nifurtimox and Benznidazole. They
      both has proven efficacy for acute face treatment, with different security profiles. There
      are not enough adequate studies comparing both drugs made in a large number of subjects.
      Investigators will study 900 patients treated with both drugs and compare security and
      efficacy in a retrospective cohort.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">February 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Nifurtimox versus Benznidazole serologic, parasitemia and clinical response for treatment in patients</measure>
    <time_frame>Patients treated from 1984 to 2017</time_frame>
    <description>To compare Nifurtimox versus Benznidazole treatment efficacy, by measuring serologic response, parasitemia and clinical manifestations in infected patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nifurtimox versus Benznidazole security and tolerance</measure>
    <time_frame>Patients treated from 1984 to 2017</time_frame>
    <description>To compare Nifurtimox versus Benznidazole security profiles, by measuring adverse events in infected patients and comparing both groups (number of adverse reactions, type and severity of reactions)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare Chagas disease characteristics associated with treatment</measure>
    <time_frame>Patients treated from 1984 to 2017</time_frame>
    <description>To describe source of infection, age of acquisition of parasite, diagnosis time frame and clinical manifestations that may be associated with treatment response and compare both groups</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Chagas Disease</condition>
  <arm_group>
    <arm_group_label>Nifurtimox</arm_group_label>
    <description>Patients treated with Nifurtimox from 1984 to 2017</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Benznidazole</arm_group_label>
    <description>Patients treated with Benznidazole from 1984 to 2017</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical Manifestations</intervention_name>
    <description>Clinical manifestations in patients treated with Nifurtimox and Benznidazole</description>
    <arm_group_label>Benznidazole</arm_group_label>
    <arm_group_label>Nifurtimox</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Serologic response</intervention_name>
    <description>Serologic response in patients treated with Nifurtimox and Benznidazole</description>
    <arm_group_label>Benznidazole</arm_group_label>
    <arm_group_label>Nifurtimox</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Direct method</intervention_name>
    <description>Direct method tests in patients treated with Nifurtimox and Benznidazole</description>
    <arm_group_label>Benznidazole</arm_group_label>
    <arm_group_label>Nifurtimox</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Adverse events</intervention_name>
    <description>Adverse events in patients treated with Nifurtimox and Benznidazole</description>
    <arm_group_label>Benznidazole</arm_group_label>
    <arm_group_label>Nifurtimox</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All pediatric patients with criteria to receive treatment (Chagas infection confirmed) that
        received treatment and completed follow-up at Parasitology and Chagas department of
        Children's Hospital Ricardo Gutierrez, Argentina.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Patients between 0 and 18 years of age with confirmed Chagas disease (defined as patients
        under 8 months with positive parasitemia or older with 2 positive different techniques for
        serology) that received treatment with Nifurtimox or Benznidazole.

        Exclusion Criteria:

        - Patients that abandoned follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Parasitology and Chagas Service, Buenos Aires Children´s Hospital Ricardo Gutierrez</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1425</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Altcheh, Phd MD</last_name>
      <phone>+54 01149634122</phone>
      <email>jaltcheh@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jaime Altcheh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Facundo Garcia Bournissen, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Samanta Moroni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillermo Moscatelli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 14, 2020</study_first_submitted>
  <study_first_submitted_qc>February 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2020</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital de Niños R. Gutierrez de Buenos Aires</investigator_affiliation>
    <investigator_full_name>Dr Jaime Altcheh</investigator_full_name>
    <investigator_title>PHD MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chagas Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

